Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 18/20 | 1.00 |
| ▸ | MAP2K2 | P36507 | 15/20 | 1.00 |
| ▸ | PIM1 | P11309 | 1/20 | 0.61 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.61 |
| ▸ | BRAF | P15056 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.58 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.58 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3762426 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL6844480 | 0.88 | MAP2K1 (0.79) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL5677719 | 0.88 | MAP2K1 (0.79) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL188505 | 0.87 | MAP2K1 (1.00) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL29413559 | 0.87 | MAP2K1 (1.00) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL29413395 | 0.87 | MAP2K1 (0.80) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL1488448 | 0.87 | MAP2K1 (0.80) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL30505247 | 0.87 | MAP2K1 (1.00) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL6185039 | 0.86 | MAP2K1 (0.76) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL6314060 | 0.86 | MAP2K1 (0.78) | MAP2K1MAP2K2PIM1CAMK2BBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115803024-B | Compositions comprising aryl amide derivatives | 中外制药株式会社 | 2025-01-10 | — | — | CN | disclosed |
| CN-114929669-B | Aryl amide derivatives with antitumor activity | 中外制药株式会社 | 2024-11-29 | — | — | CN | disclosed |
| CN-116194095-B | Co-administration of Midamatinib with lififensine for the treatment of cancer | 百济神州有限公司 | 2024-09-13 | — | — | CN | disclosed |
| US-12037306-B2 | Methods of treating neurofibromatosis type 1 with N-((R))-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide | WARNER-LAMBERT COMPANY LLC (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| CN-117279630-A | Dispersible formulations of N- ((R) -2, 3-dihydroxypropoxy) -3, 4-difluoro-2- (2-fluoro-4-iodo-phenylamino) -benzamide and uses thereof | 斯普林渥克斯治疗股份有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-117083264-A | Crystalline solids of the MEK inhibitor N- ((R) -2, 3-dihydroxypropoxy) -3, 4-difluoro-2- (2-fluoro-4-iodo-phenylamino) -benzamide and uses thereof | 斯普林渥克斯治疗股份有限公司 | 2023-11-17 | — | — | CN | disclosed |
| EP-4274567-A1 | FORMS AND FORMULATIONS OF A TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITOR | Sumitomo Pharma Oncology, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| CN-116472292-A | Modified proteins and protein degrading agents | 上海睿跃生物科技有限公司 | 2023-07-21 | — | — | CN | disclosed |
| EP-4186506-A1 | COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-31 | — | — | EP | disclosed |
| US-20230100458-A1 | NOVEL ANTHRANILIC AMIDES AND THE USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-03-30 | — | — | US | disclosed |
| CN-115803024-A | Composition comprising arylamide derivatives | 中外制药株式会社 | 2023-03-14 | — | — | CN | disclosed |
| US-20230057177-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2023-02-23 | — | — | US | disclosed |
| CN-115380117-A | Methods of treating PSMA-expressing cancers | 恩多塞特公司 | 2022-11-22 | — | — | CN | disclosed |
| CN-109563088-B | Multifunctional inhibitors of MEK/PI3K and mTOR/MEK/PI3K and therapeutic uses | 密歇根大学董事会 | 2022-10-11 | — | — | CN | disclosed |
| US-11465978-B2 | Anthranilic amides and the use thereof | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2022-10-11 | — | — | US | disclosed |
| CN-114929669-A | Arylamide derivatives having antitumor activity | 中外制药株式会社 | 2022-08-19 | — | — | CN | disclosed |
| US-20220257543-A1 | DISPERSIBLE FORMULATIONS OF N-((R)-2,3-DIHYDROXYPROPOLY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODO-PHENYLAMINO)-BENZAMIDE AND USES THEREOF | SpringWorks Therapeutics Inc. (US) | 2022-08-18 | — | — | US | disclosed |
| WO-2022150801-A1 | FORMS AND FORMULATIONS OF A TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITOR | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022018875-A1 | ARYLAMIDE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CELL PROLIFERATION DISEASES | 中外製薬株式会社 | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | MAP2K1 4140/4885MAP2K2 4169/4885PIM1 1583/4885 |
| US-12037306-B2 | Methods of treating neurofibromatosis type 1 with N-((R))-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide | VHL, NRAS, KRAS | MAP2K1 3438/4885MAP2K2 3378/4885PIM1 3279/4885 |
| US-20220257543-A1 | DISPERSIBLE FORMULATIONS OF N-((R)-2,3-DIHYDROXYPROPOLY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODO-PHENYLAMINO)-BENZAMIDE AND USES THEREOF | FLNA, QDPR, DUT | MAP2K1 4460/4885MAP2K2 3808/4885PIM1 3602/4885 |
| US-20230100458-A1 | NOVEL ANTHRANILIC AMIDES AND THE USE THEREOF | API5, MAPKAPK5, MAP3K5 | MAP2K1 315/4885MAP2K2 144/4885PIM1 1919/4885 |
| US-11465978-B2 | Anthranilic amides and the use thereof | MAPKAPK5, MAP3K5, API5 | MAP2K1 301/4885MAP2K2 149/4885PIM1 1728/4885 |
| US-20230057177-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | MAP2K1 4140/4885MAP2K2 4169/4885PIM1 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.